Impaired Catalytic Function of Activated Protein C: A New In Vitro Manifestation of Lupus Anticoagulant

• Published in: Blood 1989-11, Vol.74 (7), p.2426-2432
• Main Authors: Marciniak, Ewa, Romond, Edward H.
• Format: Article
• Language: English
• Subjects: Autoantibodies - immunology; Biological and medical sciences; Blood Coagulation Factors - immunology; Blood Platelets - physiology; Catalysis; Factor Va - metabolism; Hematologic and hematopoietic diseases; Humans; Lupus Coagulation Inhibitor; Lupus Erythematosus, Systemic - immunology; Medical sciences; Phospholipids - physiology; Platelet diseases and coagulopathies; Protein C - physiology
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V74.7.2426.2426

Lupus anticoagulant (LA), an antibody against anionic phospholipid with anticoagulant laboratory manifestations, is paradoxically associated with a high incidence of thrombosis. In the present study we analyzed the phospholipid- and platelet-dependent degradation of factor Va following clotting in plasma from 15 consecutive patients with LA to provide evidence for a distinct procoagulant effect of the antibody. After clotting with 25 µg phospholipid/mL, all samples containing LA showed markedly decreased rates of factor Va degradation (k = 0.01 to 0.14 min–1v 0.27 to 0.35 min-1 in controls). Also with higher phospholipid concentrations (up to 100 µg/mL), as well as in the presence of platelets (5 to 33 × 107/mL), significantly less of the procoagulant activity disappeared per unit of time in samples with LA than in controls. Plasma with LA was to a variable extent capable of decreasing or abolishing factor Va inhibition in normal plasma. Most importantly, exogenous activated protein C failed to correct the ineffective factor Va destruction despite adequate protein S levels. These data suggest that LA prevents the formation of the complex essential for rapid proteolysis of factor Va both on phospholipid and on the platelet membrane, thereby compromising the catalytic function of activated protein C. Our findings offer a new opportunity for a more comprehensive evaluation of patients with antiphospholipid antibody in defining the pathogenesis of thrombosis in this clinical condition.